Glembatumumab vedotin - Celldex Therapeutics Inc

Drug Profile

Glembatumumab vedotin - Celldex Therapeutics Inc

Alternative Names: CDX-011; CR 011 ADC; CR 011-vcMMAE; CR011-vcMMAE immunotoxin; Glemba; Glembatumumab; GV

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CuraGen Corporation
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Malignant melanoma; Osteosarcoma; Squamous cell cancer; Uveal melanoma

Most Recent Events

  • 16 Apr 2018 Discontinued - Phase-I/II for Squamous cell cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 16 Apr 2018 Discontinued - Phase-II for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada, Spain, United Kingdom, Belgium, France, Germany, Italy (IV)
  • 16 Apr 2018 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top